Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer - Violet, J; Sandhu, S; Iravani, A (J Nucl Med, 2019)
et al.